Editor of Patient Care Online.
2025 ACOG Annual Clinical & Scientific Meeting: What You May Have Missed
From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed from ACOG 2025.
Clesrovimab Wins FDA Approval for Prevention of RSV LRTD in Infants During First RSV Season
The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.
Q&A: Cumulative Life Course Impairment of Atopic Dermatitis with Mona Shahriari, MD
RAD 2025: As expert dermatologist Shahriari explains it, eczema may be just another rash on your schedule but for a patient, it could be the reason they don't leave the house.
Chronic Hand Eczema: Clinical Insights and Future Directions from RAD 2025
RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.
Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study
RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.
Beyond the Rash: Collaborative Insights on Pediatric Atopic Dermatitis
RAD 2025: Lisa Swanson, MD, shares insights on pediatric atopic dermatitis, addressing questions from both a dermatologist's and an allergist's perspective.
Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care
RAD 2025: Mobile health data reveal a troubling decline in systemic treatment for moderate-to-severe atopic dermatitis, underscoring issues in access and clinical inertia.
Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color
Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.
Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years
RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.
Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.
Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures
RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.
Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment
RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.
Patient Survey Highlights Importance of Itch Relief, Personalized Guidance in Atopic Dermatitis Treatment
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.
Long-Term Roflumilast Data Show Durable Efficacy in Young Children and Adults with Atopic Dermatitis
RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.
Women’s Health Takeaways for Primary Care: Expert Insights from ACOG 2025
Hear expert takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.
Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds
A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.
The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship
Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.
Social Determinants of Health Affect Use of HRT During Menopause, Study Suggests
Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.
Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.
Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose
Your daily dose of the clinical news you may have missed.
Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD
ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.
ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia
A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.
OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer
ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.
Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.
Novel Resorbable Sinonasal Implant Significantly Reduces Symptoms in Treatment-Resistant CRS
Lyra Pharmaceuticals designed the implant, which provides 6 months of continuous delivery of the anti-inflammatory mometasone furoate.
New-Onset T2D Tied to Higher Risk of Obesity-Related Cancer: Daily Dose
